Tumor-initiating cells (TICs) contribute to drug resistance and tumor recurrence in cancers, thus experimental approaches to dissect the complexity of TICs are required to design successful TIC therapeutic strategies. Here, we show that miRNA-3 0 UTR sensor vectors can be used as a pathway-based method to identify, enrich, and analyze TICs from primary solid tumor patient samples. We have found that an miR-181a high subpopulation of cells sorted from primary ovarian tumor cells exhibited TIC properties in vivo, were enriched in response to continuous cisplatin treatment, and showed activation of numerous major stem cell regulatory pathways. This miRNA-sensor-based platform enabled high-throughput drug screening leading to identification of BET inhibitors as transcriptional inhibitors of miR-181a. Taken together, we provide a valuable miRNA-sensor-based approach to broaden the understanding of complex TIC regulatory mechanisms in cancers and to identify miRNA-targeting drugs.
INTRODUCTION
Tumor-initiating cells (TICs), or cancer stem cells, are subpopulations of cancer cells that are enriched in stem-like properties and drive tumor recurrence in various cancers (Bonnet and Dick, 1997; Al-Hajj et al., 2003; Kreso and Dick, 2014) . Dissecting the complexities underlying TIC function is critical toward developing pharmacological strategies that can eradicate these cells. Several challenges in understanding TIC functions have emerged over the last few years as identified by various TIC studies across cancers, the most important of which in this context are TIC heterogeneity and TIC plasticity (Stewart et al., 2011; Meacham and Morrison, 2013) . Enrichment of TICs based on pathway activity is an emerging approach in TIC research that offers a potential platform to study TICs in the context of heterogeneity and uncover therapies that selectively target this population of cells (Vermeulen et al., 2010; Tang et al., 2015) . Existence of functional crosstalk between major stem cell regulatory pathways and the need for reliable indicators to determine the activity status of the pathway of interest in TIC clones as assessed in standard readout assays (e.g., flow cytometry/reporter assays) are main barriers in the pathway-based TIC study approach. Hence, identifying molecular entities that can regulate several pathways simultaneously coupled with reliable readout properties can greatly improve the understanding of TIC function in cancers. microRNAs (miRNAs) can be interesting candidates in this context and can offer study approaches that can potentially overcome the barriers in pathway-based TIC research.
miRNAs are small RNA molecules that mainly regulate post-transcriptional gene silencing by binding to the 3 0 UTR of their potential targets, resulting in target mRNA degradation or translational repression (Ha and Kim, 2014) . A single miRNA can thus affect multiple pathways and, not surprisingly, miRNAs are implicated in regulation of various aspects of tumorigenesis including regulation of TIC properties in many cancers (Yu et al., 2007; Shimono et al., 2009; Yin et al., 2010; Tung et al., 2017; Chen et al., 2017) . Tumor subpopulations could be composed of cells with varying degrees of miRNA activity; hence, overexpression or knockdown of miRNAs to the same extent in all these populations may not reflect the true biology of miRNAs in these settings. Since 3 0 UTR-driven activity is one of the defining traits of miRNA functions, isolation and characterization of TIC subpopulations in cancers based on miRNA 3 0 UTR activity can overcome the barriers associated with pathway-based approaches in TIC research. Isolating target cell populations based on miRNA activity using miRNA switches has been reported in physiological settings (Miki et al., 2015) . Studying TICs in hematological malignancies utilizing a miRNA 3 0 UTR activity-based approach has also been reported (Lechman et al., 2016) . However, the application of miRNA activitybased tools to enrich for TICs in solid tumors or uncover miRNA-targeted drugs has not been explored to date. Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, in which TICs have been shown to be involved in the emergence of chemotherapy resistance and tumor recurrence, and to contribute to poor patient survival (Silva et al., 2011; Garson and Vanderhyden, 2015) . One of the striking features of EOC is that even though the disease is heterogeneous in origin, the treatment approach has remained mostly homogeneous to date, i.e., platinum-based therapy has remained the mainstay of EOC treatment in the last few decades and resistance to platinum-based therapies continues to be the major barrier to eradication of this disease (Cunnea and Stronach, 2014) . Thus, lack of TIC-targeted therapies may represent one of the main reasons for poor patient survival, and experimental approaches are required to dissect TIC function in order to develop drugs that could eradicate these cells. We have previously identified that high miR-181a expression correlates with poor survival in the high-grade serous ovarian cancer (HGSOC) subtype of EOC and that miR-181a is enriched in recurrent HGSOC tumors (Parikh et al., 2014) . This correlation has also been shown in numerous other cancers (Pop-Bica et al., 2018) . Most recently a comprehensive TCGA analysis of 12,000 tumor samples from 33 different cancers showed that a high level of miR-181 family members correlated with an mRNA stemness signature (Malta et al., 2018) , and miR-181a has been identified as a regulator of TICs in hepatic cancer (Ji et al., 2010) , thus suggesting that this miRNA family could be involved in driving TIC properties. In the current study, we have developed a miRNA-sensor-based platform driven by miR-181a 3 0 UTR activity to enrich TICs in primary EOC tumors and have identified miR-181a as a TIC therapeutic target. We further utilized the miR-181a sensor as a pharmacological screening platform to identify upstream regulators of miR-181a function, and uncovered that BET inhibitors transcriptionally regulate miR-181a.
RESULTS
miR-181a Induces Stem-like Properties in Nontransformed Fallopian Tube Secretory Epithelial Cells Deregulation of adult stem cell drivers is one of the traits observed in TICs. Several regulators of TICs identified to date in cancers are in fact the ones that regulate stem-like properties under physiological conditions in their respective tissues (e.g., LGR5) (Barker et al., 2007; Shimokawa et al., 2017) . Fallopian tube secretory epithelium (FTSE) has been identified as the origin of HGSOC, which is the most common subtype of EOC (Perets et al., 2013) . Existence of a stem cell niche in the fallopian tube suggests a TIC-based origin of HGSOC (Flesken-Nikitin et al., 2013) . Hence, identifying regulators of stem-like properties in FTSE cells can lead to characterization of TIC regulators in EOC. Thus, to investigate the potential role of miR-181a in driving TIC properties in EOC, we first looked at the effects of miR-181a upregulation in non-transformed FTSE cells (FTSE shp53-R24C) (Karst et al., 2011) . We focused on miR-181a, given that this miR-181 family member is the most highly expressed in HGSOC tumors ( Figure S2A ). Upon stable miR-181a overexpression in FTSE cells we found increased expression of ALDH1A1 and CD133, established as TIC markers in EOC ( Figure 1A ) (Choi et al., 2015) . We next looked at sphere-initiating cell frequency in miR-181a-FTSE cells by utilizing in vitro limiting dilution tumor sphere-formation assay (Rota et al., 2012) . Extreme limiting dilution analysis (ELDA) (Hu and Smyth, 2009) found that miR-181a increased sphere-initiating cell frequency by 10-fold ( Figures 1B and 1C) . Conversely, stable downregulation of miR-181a decreased the expression of TIC markers ALDH1A1, CD133, and LGR5 (Figure 1D) , which was associated with an 18-fold decrease in sphere-initiating cell frequency in FTSE-miR-181a cells ( Figure 1E ), confirming specificity of miR-181a induced stem-like phenotype. Next, to assess whether miR-181a is a critical driver of TIC properties in EOC, we studied the effects of miR-181a overexpression on TIC properties in the OV81.2 primary HGSOC cell line model (Nagaraj et al., 2015a) . OV81.2 cells exhibit high ALDH activity and form tumors at low cell numbers; however, tumorinitiation ability was significantly higher in OV81.2-miR181a overexpressed cells as compared with OV81.2-control cells (45-fold increase in tumor-initiating cell frequency, p = 0.001) ( Figures 1F and 1G ). These results support miR-181a as a regulator of stem-like properties in FTSE cells and primary HGSOC cells and suggest that miR-181a deregulation could underlie TIC function in EOC. Thus, we would predict that ovarian tumor cells with high miR-181a activity could potentially be enriched in TIC properties.
miR-181a Sensor Enriches for Tumor-Initiating Cells in Ovarian Cancer
We next set out to isolate miR-181a high versus miR-181a low subpopulation of tumor cells from ovarian tumors by using an miRNA sensor platform (Mullokandov et al., 2012) . The miR-181a sensor ( Figure S1 ) enabled isolation of miR181a high and miR-181a low cells from both OCI-P5X
(primary HGSOC cells [Ince et al., 2015] ) and HEYA8 (established TIC study model in ovarian cancer [Chau et al., 2013] ) with 4-fold increase in miR-181a expression (Figures 2A and 2B) . Similar to what was observed in the TCGA dataset ( Figure S2A ), miR-181a was the predominant miRNA expressed in both miR-181a high and miR-181a low primary HGSOC OCI-P5X cells as compared with miR181b and miR-181c ( Figure S2B ), whose expression levels were below reliable detectable levels. Hence, we focused on studying miR-181a in the current study. The ability to initiate tumors at low cell densities is a hallmark of TICs, thus we first looked at tumor-initiation capacity of miR181a sensor-sorted OCI-P5X primary cells. OCI-P5X miR181a high cells were able to initiate tumors with as few as 1,000 cells whereas OCI-P5X miR-181a low cells were unable to initiate tumors even at 100,000 cells ( Figure 2C ). 2F ). miR-181a expression in miR-181a high tumors was 4-fold higher than that of miR-181a low tumors (data not shown). This is similar to 4-fold difference observed in high and miR-181a low HEYA8 cells were sorted into single-cell-capture microfluidic devices and their growth was monitored daily for 15 days. Representative photomicrographs (G) of miR-181a low /mCherry high cell divisions showing these cells were only observed to divide to yield two miR-181a low /mCherry high cells. In contrast, miR-181a high /mCherry low cells divided both symmetrically to yield other mCherry-negative cells and asymmetrically to yield mCherry dim cells. (H) Summary of all divisions observed after 4 days of growth. **p < 0.005, ***p < 0.005.
miR-181a expression between miR-181a
high and miR181a low cells in vitro. This suggests that miR-181a low cells are unlikely to revert to miR-181a high cells in vivo. We next assessed asymmetric cell division in these two populations, given that it is one of the defining traits of TICs and ovarian TICs are known to exhibit asymmetric cell division (Choi et al., 2015) . We found that miR-181a low ovarian tumor cells exhibited 100% symmetric cell division (relative to miR181a) whereas miR-181a high ovarian tumor cells exhibited both symmetric (65%) and asymmetric (35%) divisions, further supporting that these cells are enriched in TIC properties (Figures 2G and 2H) . In vitro proliferation rate did not differ between miR-181a low and miR-181a high ovarian tumor cells, confirming that the differences in TIC properties between these two populations are not due to differences in proliferation ability ( Figure S3 ).
Collectively, these results demonstrate the ability of miRNA 3 0 UTR sensor to isolate TICs from primary tumors and also identify miR-181a as a regulator of TIC properties in EOC.
miR-181a Sensor Enriches for Multiple TIC Regulatory Signaling Pathways in Primary HGSOC Cells
Since the miR-181a sensor enabled isolation of ovarian TICs, we next looked at the pathways enriched in miR181a sensor-sorted primary HGSOC cells by microarray analysis to determine the ability of miRNA sensor to potentially enrich for multiple TIC pathways. PANTHER gene expression analysis of the top 50 genes upregulated or downregulated in miR-181a high primary HGOSC cells identified several classes of genes altered in these cells as compared with miR-181a low primary HGSOC cells (Figure 3A) . Furthermore, gene set enrichment analysis (GSEA) of the gene expression profile of miR-181a high and miR-181a low primary HGSOC cells revealed several known TIC regulatory pathways to be enriched in miR-181a high cells, which correlated with the known fact that miRNAs regulate several pathways ( Figure 3B ). Epithelial mesenchymal transition (EMT) and transforming growth factor b (TGF-b) pathways were upregulated in miR-181a high cells, which correlated with our previous results showing that miR-181a induces EMT in ovarian cancer by activating TGF-b through the direct targeting of the inhibitory SMAD, SMAD7, thus confirming the functional reliability of the gene expression data (Parikh et al., 2014) . In addition, several known stem cell regulatory pathways such as interferon-a (IFN-a), tumor necrosis factor a (TNF-a), PI3K/AKT/mTOR, and MYC were upregulated in miR181a high cells, showing that miR-181a sensor can enrich for multiple TIC regulatory pathways (Zhu et al., 2014; Lee et al., 2012; Xia and Xu, 2015; Dubrovska et al., 2009; Wang et al., 2008; Yang et al., 2017; Nair et al., 2014) . The pathways enriched in miR-181a high HGSOC cells could be due to combination of a direct effect of the miRNA and also an indirect effect due to potential crosstalks between the pathways. Therefore, we examined the top 100 downregulated genes in miR-181a high HGSOC cells in comparison with miR-181a predicted targets (miRWalk database), which revealed that 30% of the downregulated genes in miR-181a high HGSOC cells are predicted miR-181a targets (Table S1 ). Thus, enrichment of diverse TIC regulatory pathways directly or indirectly by miR-181a could contribute to increased TIC properties of miR-181a high ovarian tumor cells.
miR-181a Sensor Enables Analysis of Ovarian Tumor Cell Response to Cisplatin in Real Time
The ability of TIC populations to survive standard cytotoxic chemotherapy leads to disease recurrence and poor outcomes. Thus, given that miR-181a high ovarian tumor cells were enriched in TIC properties and miR-181a sensor provides a real-time platform to assess endogenous miR181a activity, we utilized this platform to study the effects of long-term cisplatin treatment on miR-181a activity in ovarian tumor cells. Long-term culture of miR-181a sensor-transduced HEYA8 cells in the presence of cisplatin (HEYA8 miR-181a-sensor-CP10) increased the miR-181a high subpopulation, which correlated with increased miR-181a expression ( Figures 4A and 3B ). Control sensor-transduced HEYA8 cells did not exhibit a decrease in the mCherry population upon long-term cisplatin treatment (HEYA8 control sensor-CP10) ( Figure 4A ). We next sorted mCherry high and mCherry low populations from HEYA8 miR-181a-sensor-CP10 cells ( Figure 4C ) and assessed their sphereinitiating cell frequency. HEYA8-miR-181a-sensor-CP10-mCherry low (miR-181a high ) cells exhibited increased sphere-initiating cell frequency (12-fold) as compared with HEYA8-miR-181a-sensor-CP10-mCherry high (miR181a low ) cells, further confirming enrichment of miR181a high TICs in response to cisplatin treatment ( Figure 4D ). Figure 4G ). These findings raise the possibility that targeting miR-181a could overcome the barrier of tumor recurrence by inhibiting TICs in EOC.
miRNA-Sensor-Based High-Throughput Therapeutic Screen Identifies BET Inhibitors as Potential Inhibitors of miR-181a
Even though transcriptional regulation of miRNAs forms a critical step in the regulation of miRNA functions, this aspect is not very well understood. Identifying upstream regulatory elements of miRNAs can lead to identification of inhibitors of these regulatory elements, thus greatly enhancing the efficacy of miRNA-targeted therapeutics. Current methodologies to study upstream regulatory elements of miRNAs are mainly limited to a candidate gene approach whereby selected genes/pathways are studied as potential drivers of miRNA expression, thus limiting the identification of miRNA inhibitors (Niu et al., 2016) . The lack of reliable platforms to identify global regulators of miRNA transcription is the main barrier toward deciphering upstream regulatory elements involved in miRNA transcription. This, in turn, translates into the lack of miRNA-targeting drugs in oncology. Since our results identified miR-181a as a TIC therapeutic target in EOC, we next set out to test the utility of the miRNA sensor model as a tool to identify inhibitors of miR-181a that can be potentially evaluated as TIC-targeting drugs. For this approach, we first established a 384-well functional platform in which miR-181a inhibition in miR181a high (mCherry low ) ovarian tumor cells could be monitored as an increase in mCherry fluorescence readout ( Figure S4 ). Using this 384-well platform, we treated the miR-181a high ovarian tumor cells with a chemical library consisting of 3,114 compounds and looked for candidate drugs that increased mCherry fluorescence, thus identifying them as potential inhibitors of miR-181a expression (Table S2) . Preliminary screening revealed 32 hits (Figure S5) . Further correction for false-positive hits due to potential autofluorescence properties of the drugs translated into eight final hits ( Figure 5A and Table S2 ). Interestingly, all eight hits have been previously linked with targeting TICs (Naujokat and Steinhart, 2012; Yokoyama et al., 2016) and SC144, an inhibitor STAT3 that regulates miR-181a transcription (Niu et al., 2016) , supports the functional reliability of the miRNA-sensor-screening platform. Furthermore, four of the eight hits were epigenetic regulators or bromodomain and extra-terminal motif (BET) inhibitors, suggesting an epigenetic regulation of miR-181a by the BET protein family that has not been reported to date in either cancer or normal physiological context.
We next assessed the correlation of cell counts versus mCherry fluorescence upon treatment with increasing doses of the identified eight hits. Six hits including the three BET inhibitors exhibited R 2 value of >0.7 in the correlation analysis, further suggesting that BET proteins could be regulators of miR-181a transcription ( Figure 5B and Table S2 ). Sarcatinib and NSC319726 exhibited weak correlation and hence were excluded from further analysis. We further confirmed that these six hits increased mCherry expression in miR-181a high cells ( Figure 5C and Table S2 ).
miR-181a Is a Target of BET Inhibitors Across Cancers
We next set out to validate whether miR-181a is a target of BET inhibitors. BET inhibitors increased mCherry fluorescence in the miR-181a high subpopulation sorted from OVCAR3, HEYA8, and primary HGSOC OCI-P5X cells, further validating the miRNA-sensor-screening results identifying BET inhibitors as inhibitors of miR-181a in EOC ( Figure 6A ). We subsequently confirmed that BET inhibitors decreased the expression of miR-181a by Taqman miRNA assays ( Figure 6B ). In addition, we looked at the effect of BET inhibition on miR-181a promoter activity (Presnell et al., 2015; Bert et al., 2000) to assess whether miR-181a is a transcriptional target of BET inhibitors. BET inhibitors decreased miR-181a promoter activity by 70% in the miR-181a high subpopulation sorted from OVCAR3,
showing that miR-181a is a transcriptional target of BET inhibitors in EOC. Contrastingly, cisplatin increased miR181a promoter activity in these cells by more than 1.5-fold, in accordance with the increased miR-181a expression seen in cisplatin-resistant EOC tumor cells ( Figure 6C ). Furthermore, BET inhibition decreased miR-181a promoter activity in the miR-181a high subpopulation sorted from OCI-P5X (90%) and HEYA8 cells (80%), and also in FTSE cells (90%) ( Figure 6D ). To assess whether miR181a is a conserved target of BET proteins across cancers, we looked at the effect of BET inhibition on miR-181a promoter activity in breast cancer cells (MDA-MB-231) and lung cancer cells (H358). BET inhibition decreased miR181a promoter activity in both breast cancer (70%) and lung cancer cells (90%), thus identifying a hitherto unknown function of BET protein family as regulators of miR-181a transcription across cancers ( Figure 5D ). Given that the mechanism of BET inhibitors is through the disruption of bromodomain proteins on to acetylated chromatin, we next examined whether the miR-181a promoter was acetylated. H3K27ac chromatin immunoprecipitation sequencing revealed that the miR-181a promoter was acetylated and, interestingly, this acetylation increased in cisplatin-resistant cells ( Figure S6 ). Since miR-181a is implicated in regulation of various aspects of tumorigenesis across cancers, these results suggest that the BET-miR181a axis could be a functionally conserved regulatory axis in cancers; hence, BET inhibitors could potentially be evaluated as small-molecule inhibitors of miR-181a function in cancers or miR-181a could be a potential biomarker for response.
DISCUSSION
Isolation, characterization, and targeting of TIC clones present in a tumor are a major barrier to complete eradication of all the cancer cells present in a patient. TIC regulators can differ in patients due to intertumor and intratumor heterogeneity. An miRNA sensor approach can enhance the understanding of TIC functions in cancers because (1) miRNAs regulate multiple pathways, and thus miRNA activity can potentially enrich for multiple TIC clones in primary tumors, and (2) miRNA function can be assayed by 3 0 UTR activity, and hence status of miRNA function can be reliably assayed in TIC clones in real time in response to genetic/pharmacological modulation. Our results also demonstrate the importance of including non-transformed cell models to identify TIC regulators in cancers. Increased stem-like properties by miR-181a in non-transformed FTSE cells prompted us to investigate stem-like properties in miR-181a high and miR-181a low subpopulations in EOC tumors, thus identifying miR-181a as a regulator of TIC functions. Several predicted targets of miR-181a were enriched in miR-181a high primary HGSOC cells. For example, PARK2 (Parkin), which was one of the predicted miR-181a targets that was downregulated in miR-181a high HGSOC cells and has been characterized as a target of miR-181a in neuroblastoma cells (Cheng et al., 2016) , is a negative regulator of PI3K/Akt pathways (Gupta et al., 2017) . In addition, loss of PARK2 is reported to be associated with increased levels of cytokines such as TNF-a . Hence, downregulation of PARK2 in miR-181a high HGSOC cells could be one of the mechanisms activating TNF-a and PI3K/Akt pathways in these cells. Furthermore, IRF8, which is a predicted miR-181a target downregulated in miR-181a high cells, is a negative regulator of the IFN pathway and could contribute to the increased IFN-a pathway we observed in miR-181a high HGSOC cells (White et al., 2016) . Furthermore, ongoing studies in our laboratory have identified functional interaction of miR-181a with MYC in regulating HGSOC pathogenesis, which correlates with enrichment of the MYC pathway in miR-181a high HGSOC cells (our unpublished data). In addition, it has been previously shown that miR-181 is sharply induced in Myc-induced differentiated embryonic stem cells and tumor cells (Lin et al., 2009) ; thus, enrichment of the MYC pathway in the miR-181a high HGSOC cells may be due to the upstream regulation of miR-181a by MYC. Activation of the Akt pathway by miR181a has been reported, and hence this pathway could function downstream of miR-181a in HGSOC (Strotbek et al., 2017) . Activation of PI3K/Akt pathway is known to induce MYC stabilization, and synergy between these two pathways is reported in cancers (Tsai et al., 2012; Sander et al., 2012) , suggesting that crosstalk between enriched pathways could also be an important contributor to the increased TIC phenotype in miR-181a high HGSOC cells.
In this study we have identified a hitherto unknown role of miR-181a in driving tumor recurrence in HGSOC, and show that (1) miR-181a
high ovarian tumor cells are enriched in TIC properties and (2) the miR-181a high subpopulation of ovarian tumor cells is enriched in response to cisplatin treatment. miR-181a is reported to be induced by cisplatin treatment in lung cancer (Galluzzi et al., 2010) , and our results show that cisplatin induces miR-181a promoter activity. Thus, both selection of miR-181a high cells and induction of miR-181a in response to cisplatin treatment can contribute to enrichment of miR-181a high cells upon cisplatin treatment. Moreover, miR-181a could be a common driver of both intrinsic stem-like properties in ovarian tumor cells, and also acquired stem-like properties in response to selection pressure induced upon cisplatin treatment. These data have been recently supported and expanded to other cancers through the comprehensive TCGA analysis of 12,000 tumor samples from 33 different cancers, which revealed that miR-181 expression in several different cancers correlated with a high mRNA stemness index (Malta et al., 2018) . Hence, miR-181a inhibition could be evaluated as an miRNA therapeutic approach targeting TICs to overcome the barrier of tumor recurrence in EOC as well as several other cancers. One of the main barriers for advancements in miRNA therapeutics is the lack of in-depth understanding of transcriptional regulation of miRNAs in both physiological and cancer settings. Here, we have identified a role for BET inhibitors as miRNA modulators in EOC, in particular as miR-181a inhibitors. BET inhibitors are being explored as potential anti-cancer drugs in clinical trials across multiple cancers (Fujisawa and Filippakopoulos, 2017) . BET inhibition is being evaluated as a potential therapeutic strategy in EOC, and BET inhibition is reported to decrease the expression of stemness-regulating genes and to overcome cisplatin resistance in EOC (Yokoyama et al., 2016) . The miR-181a high subpopulation in EOC could represent a potential TIC clone that could be targeted by BET inhibitors. However, since BET proteins regulate a multitude of cellular processes in cancers (Fujisawa and Filippakopoulos, 2017) , several miRNAs could be targeted by BET inhibition in EOC. Changes in miRNAome induced by BET inhibition are not understood in EOC and, hence, functional characterization of miRNAome targeted by BET inhibitors in EOC is important to establish these drugs as miRNA-targeting drugs in EOC. Since miRNAs are established as reliable biomarkers in various cancers including EOC (Nagaraj et al., 2015b) , miRNAs can be employed as biomarkers for both patient stratification and monitoring therapeutic efficacy of BET inhibition in EOC, thus enhancing the translational potential of BET inhibition in EOC with potential extension to other cancers. By developing an miRNA-3 0 UTR sensor platform and using it to explore the role of miR-181a in EOC, we have (1) simplified the understanding of functional complexity in TICs and expedited the journey toward near complete isolation of multiple TIC clones in tumors, (2) identified a reliable approach to find small-molecule inhibitors of miRNA function that can greatly enhance the translational potential of miRNA therapeutics in both cancer and physiological contexts, and (3) uncovered a potential clinical biomarker for response to BET inhibitors.
EXPERIMENTAL PROCEDURES

Cell Culture and Reagents
Cells were cultured in 10-mm plates in a humidified atmosphere (5% CO 2 ) at 37 C. At 70%-90% confluence, trypsin (0.25%)/ EDTA solution was used to detach the cells from the culture plate for passaging and used for further experiments until passage 20. FTSE cells (DMEM-F12 medium), OVCAR3, HEYA8, and H358 cells (RPMI medium), and MDA-MB-231 cells (DMEM medium) were cultured in their respective media supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% PenStrep (PS) (Gibco). Primary HGSOC cells (OCI-P5X, OV236) were cultured in OCMI-L medium (Liver Tumor Culture Core, University of Miami) supplemented with 2.5% heat-inactivated FBS (Gibco) and 1% PS. OCI-P5X cells were purchased from Liver Tumor Culture Core, University of Miami. Matrigel was purchased from Corning (NY). Cisplatin was purchased from Mount Sinai Hospital Pharmacy. miR-181a lentiviral overexpression and the control vector were purchased from Biosettia (San Diego, CA). miR-181a antagomiR lentiviral vector and the control vector were purchased from Genecopoeia (Rockville, MD). miR-181a antagomir and the corresponding negative control for transient transfections were purchased from Dharmacon. BET inhibitors were purchased from Selleckchem (Houston, TX).
Tumor-Initiating Cell Assays
For limiting dilution sphere assays, a BD FACSAria II sorter was used to sort cells directly into 96-well ultra-low attachment (ULA) plates (Corning, NY) in 200 mL of mammocult medium (STEMCELL Technologies, Vancouver, Canada) per well. After indicated time points, the number of wells with tumor spheres was counted and the data were analyzed by the ELDA platform to determine the sphere-initiating cell frequency. At each cell dosage three biological replicates were used for in vitro LDA assays. Each replicate was sorted in eight wells in ULA plates per cell dosage. For in vivo tumor-initiation assays, miR-181a high and miR-181a low cells were resuspended in cell culture medium with Matrigel in 50:50 ratios and injected subcutaneously in NU/NU mice, and tumor formation was assessed. For in vivo LDA assays, ten mice were studied in each group with OCI-P5X and HEYA8 cells, and four mice were studied in each group with OV81.2 cells. Tumor volume was estimated by standard caliper measurement (V = L 3 W 2 /2). The ELDA platform was employed to determine the tumor-initiating cell frequency. Symmetric and asymmetric cell division experiments were performed as described previously (Choi et al., 2015) .
Statistical Analysis
Unless otherwise noted, data are presented as mean ± SD from three independent experiments, and Student's t test (two-tailed) was used to compare two groups (p < 0.05 was considered significant) for independent samples. 
SUPPLEMENTAL INFORMATION
Supplementary Methods
Lentiviral transduction
For lentiviral transfection, Lenti Starter Kit (System Biosciences, CA) was used. Briefly, 
Transient transfection assays
For miR-181a promoter assays, miR-181a promoter (1μg) and renilla (150ng) were cotransfected using lipofectamine RNAiMAX (Life Technologies). Luciferase activities were analyzed using the Dual-Luciferase Reporter Assay System (Promega) with data normalization to the corresponding renilla values. For miR-181a antagomiR experiments, the control antagomiR and miR-181a antagomiRs were both purchased from Dharmacon.
OVCAR3 cells were transfected with 50nM of the antagomiRs using lipofectamine
RNAiMAX. 24hrs after transfection the cells were plated in 384 well imaging plates at different cell densities and mCherry fluorescence was determined 24hrs later.
3D on top matrigel sphere formation assay
250μl matrigel was plated in 24 well plates (Corning) and after 30 min incubation at 37 0 C, 5000 cells were plated in 250μl mammocult on top of the first matrigel layer and incubated at 37 0 C for 1hr after which 500μl of 10% matrigel in mammocult was added on top. After 3 weeks, 10x10 stitch imaging was done at 10x (100 random images acquired) using a Retiga Aqua Blue camera (Q Imaging, Vancouver, BC) connected to a Leica DMI6000 inverted microscope. Individual images were taken and then a composite image was generated using the scan slide function in Metamorph Imaging Software (Molecular Devices, Downington, PA). Subsequent integrated analysis also used Metamorph software.
ALDEFLOUR Assay
ALDH activity was determined by using ALDEFLOUR assay kit (Stem cell technologies 
Screening with chemical library
Chemical Compounds
The Collection of Biologically Active Molecules (Collection3114) was compiled from LOPAC library (Millipore Sigma, USA) and Bioactive Compound Library (Selleckchem). A total of 3114 mechanistically annotated partially redundant compounds were used for screening. All compounds were dissolved in DMSO at 10mM. A final DMSO concentration of 0.1% was not exceeded in the screening assay and in hit validation experiments. Upon hit identification, all compounds were retested as 10mM stock solutions purchased from original vendor.
Measurement of drug activity
Both mCherry low and mCherry high cells were seeded at 600 cells/well in Corning 3712 384-well plates using growth media. Cells were seeded in 50μL of media using automated dispenser (MultiFlo FX, BioTek 
Cell imaging and image analysis
Fixed and stained cells were subjected to imaging and image analysis. The Operetta highcontent imaging system with a 10x objective (PerkinElmer) was used for cell imaging. 
